Cell Free Synthesis of Biologics (Paperback)

Cell Free Synthesis of Biologics: A Comprehensive Guide addresses the need for efficient production methods in biopharmaceutical manufacturing. As the demand for biologics continues to rise, traditional cell-based production systems often fall short due to high costs and complexity. This book offers a detailed exploration of cell-free protein synthesis (CFPS), providing researchers and professionals with the latest methodologies, best practices, and troubleshooting strategies necessary for successful implementation. The content is structured into comprehensive chapters that cover the historical development, technical foundations, optimization strategies, advanced technologies, and the regulatory landscape surrounding CFPS.

Each section is designed to guide users through the complexities of establishing and scaling up cell-free systems, ensuring a clear understanding of the processes involved and the potential applications in therapeutic development, diagnostics, and industrial biotechnology. This book provides pharmaceutical scientists and pharma manufacturing professionals with practical insights and innovative strategies to enhance efficiency and reduce costs in biopharmaceutical production.

• Provides comprehensive protocols for cell-free protein synthesis technologies
• Insights into regulatory considerations and compliance for biologics
• Covers strategies for optimizing production and scaling up processes
• Includes real-world applications in biomanufacturing and diagnostics
• Develops economic analysis for cost-effective biopharmaceutical production

Sarfaraz Niazi, Ph.D., is an adjunct professor at the University of Illinois and the University of Houston. He has authored 60+ major books, 100+ research papers, and 100+ patents, mainly in the fields of bioprocessing, drug discovery, drug formulations, thermodynamic systems, alcohol aging, nutraceuticals, and the treatment of autoimmune diseases. He has hands-on experience in establishing biotechnology projects, from concept to market, including FDA approval. He also serves as an advisor to major pharmaceutical and biopharmaceutical companies, regulatory agencies, and many heads of state, and is a patent law practitioner.